Back to mobile site
Get it on Google Play

FDA approves Pfizer's Tukysa as front-line maintenance for HER2+ breast cancer

October 7, 2026 12:57 PM EDT Send to a Friend
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration has approved Tukysa (tucatinib) in combination with trastuzumab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login